Taysha Gene Therapies, Inc. TSHA
4.10 USD -0.11 (-2.61%)
At closeNov 13, 2026, 4:01 PM EST
4.10 0.00 0.00%
After hours · Nov 13, 4:01 PM ET
3.98 Day range 4.33
3.46 52-week range 7.30
- YTD
- -25.45%
- 1 year
- +2.24%
News
seekingalpha.com Taysha Gene Therapies, Inc. (TSHA) Q3 2026 Earnings Call Transcript Taysha Gene Therapies, Inc. ( TSHA ) Q3 2026 Earnings Call November 12, 2026 8:30 AM EST Company Participants Sean Nolan - CEO & Chairman Sukumar Nagendran - President, Head of Research & Development…
marketbeat.com Taysha Gene Therapies Q3 Earnings Call Highlights Taysha Gene Therapies NASDAQ: TSHA expects to report pivotal trial data for its experimental Rett syndrome gene therapy TSHA-102 and provide feedback from U.S. regulators on a potential filing…
benzinga.com Taysha Gene Therapies Q3 2026 Earnings Call Transcript Taysha Gene Therapies (NASDAQ:TSHA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
globenewswire.com Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027
globenewswire.com Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus…
benzinga.com Taysha Gene Therapies Presents Multiple Encore Presentations For Its TSHA-102 Program At 55th Child Neurology Society Annual Meeting Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic…
benzinga.com Wolfe Research Initiates Coverage On Taysha Gene Therapies with Outperform Rating Wolfe Research analyst Kalpit Patel initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform rating.
benzinga.com Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) Estimate Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 44.44 percent decrease over losses…- benzinga.com Goldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13 Goldman Sachs analyst Salveen Richter maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $11 to $13.
- benzinga.com Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target Citizens analyst Silvan Turkcan reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and maintains $11 price target.
benzinga.com Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Canaccord cut Strategy's target, Barclays upgraded Watts Water, Rosenblatt boosted Comcast, Goldman…
benzinga.com Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $15 Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $12 to $15.
benzinga.com H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session U.S. stock futures up, Nasdaq 100 futures gain 2%. H.B. Fuller shares dip 8.3% on earnings release and offer to acquire Advanced Medical Solutions.
benzinga.com Why Micron Technology Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket Shares of Micron Technology Inc (NASDAQ: MU) surged in pre-market trading after reporting strong Q3 results and issuing strong guidance. Autozi Internet Technology, Focus Universal, SAGTEC GLOBAL,…
benzinga.com 9 Health Care Stocks Moving In Wednesday's After-Market Session Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-market session. The market value of their outstanding shares is at $9.7 million. Greenland Mines…- benzinga.com Taysha Gene Therapies Commences $200M Common Stock Offering Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic…
benzinga.com BMO Capital Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $14 BMO Capital analyst Keith Tapper maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $10 to $14.
benzinga.com B of A Securities Maintains Buy on Taysha Gene Therapies, Raises Price Target to $10 B of A Securities analyst Tazeen Ahmad maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $9 to $10.- benzinga.com Citizens Maintains Market Outperform on Taysha Gene Therapies, Raises Price Target to $11 Citizens analyst Silvan Tuerkcan maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and raises the price target from $8 to $11.
- benzinga.com Taysha Gene Therapies Completes Dosing In REVEAL Prival Study Of 17 Females In Developmental Plateau Population Of Rett Syndrome Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic…
benzinga.com Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls after pricing public offering of $50M. Other stocks decline in pre-market.
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com Taysha Gene Therapies Q1 EPS $(0.12) Misses $(0.10) Estimate Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 20 percent. This is a 50 percent decrease over losses of…
benzinga.com Taysha Gene Therapies To Reveal New Preclinical Data Supporting Construct Design Of TSHA-102 For Rett Syndrome At The ASGCT 2026 Annual Meeting Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic…- benzinga.com Canaccord Genuity Maintains Buy on Taysha Gene Therapies, Raises Price Target to $17 Canaccord Genuity analyst Whitney Ijem maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $14 to $17.
benzinga.com Taysha Gene Therapies Q4 EPS $(0.12) Misses $(0.10) Estimate, Sales $5.485M Beat $1.889M Estimate. Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 23.71 percent. This is a 71.43 percent decrease over…- benzinga.com Earnings Scheduled For March 19, 2026
- benzinga.com Needham Reiterates Buy on Taysha Gene Therapies, Maintains $10 Price Target Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $10 price target.
- benzinga.com Chardan Capital Maintains Buy on Taysha Gene Therapies, Maintains $12 Price Target Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $12 price target.
- benzinga.com Taysha Gene Therapies Advances TSHA‑102 Rett Syndrome Program; First Patient Dosed In REVEAL Pivotal Trial, FDA Alignment On ASPIRE Safety Data For Broad BLA, Dosing Completion Expected Q2 2026 With Longer‑Term Data Update In H1 2026 First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment advancing across multiple sitesReached written alignment with FDA on inclusion…
- benzinga.com Citizens Maintains Market Outperform on Taysha Gene Therapies, Raises Price Target to $8 Citizens analyst Silvan Tuerkcan maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and raises the price target from $6 to $8.
- benzinga.com Chardan Capital Maintains Buy on Taysha Gene Therapies, Maintains $12 Price Target Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $12 price target.
- benzinga.com Taysha Gene Therapies Q3 EPS $(0.09), Inline. Revenue $0. Cash And Equivalents $299.94M. Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 10 percent increase over losses of $(0.10) per share from the…
benzinga.com Earnings Scheduled For November 4, 2025 
benzinga.com Raymond James Initiates Coverage On Taysha Gene Therapies with Strong Buy Rating, Announces Price Target of $13 Raymond James analyst Christopher Raymond initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Strong Buy rating and announces Price Target of $13.
benzinga.com Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
benzinga.com Why Is Taysha Gene Therapies Stock Falling Friday? Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for pivotal trial.
benzinga.com Needham Reiterates Buy on Taysha Gene Therapies, Maintains $10 Price Target Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $10 price target.- benzinga.com Taysha Gene Therapies Regains Full Rights To Its Lead TSHA-102 Program In Clinical Evaluation For Rett Syndrome; TSHA-102 Has Demonstrated Compelling Part A REVEAL Phase 1/2 Safety And Efficacy Data, Received FDA Breakthrough Therapy Designation And Is Advancing With A Clear Path To Potential Registration DALLAS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus…
- benzinga.com Taysha Gene Announces Results From Supplemental Data Analysis From Part A Of REVEAL Phase 1/2 Adult/Adolescent And Pediatric Trials Evaluating TSHA-102 In Females With Rett Syndrome At CNS Annual Meeting Previously disclosed 100% response rate across all 10 patients in Part A for pivotal trial primary endpoint of gain/regain of ≥ one natural history defined developmental milestone assessed via…
- benzinga.com Demystifying Taysha Gene Therapies: Insights From 6 Analyst Reviews
- benzinga.com Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $12 Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $7 to $12.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday.- benzinga.com Needham Maintains Buy on Taysha Gene Therapies, Raises Price Target to $10 Needham analyst Gil Blum maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $8 to $10.
benzinga.com Top 2 Health Care Stocks That May Keep You Up At Night This Month - benzinga.com FDA Grants Breakthrough Therapy Designation To Taysha Gene Therapies' TSHA-102 For Rett Syndrome; On Track To Begin Patient Enrollment In Q4 2025 Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trialsFinalized FDA…
- benzinga.com What's Driving the Market Sentiment Around Taysha Gene Therapies?
- benzinga.com Is Taysha Gene Therapies Gaining or Losing Market Support?
- benzinga.com A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through 11 Analysts